Learn
Interested in participating in a psychedelic study? Here's an in-depth walk through guide so you can take actionable steps to...
Here's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4...
The Director of Research for Unlimited Sciences takes a deep dive into microdosing research to explore its effects, which may...
Introducing the Benzinga Psychedelics Capital Conference on April 19 in Miami Beach,...
This week in psychedelic business news: Filament Health scores 2nd psilocybin patent; a new psychedelics company emerges as one crumbles....
NeonMind finds that its proprietary psilocybin has the ability to target visceral fat, effectively reducing weight gain in obese subjects....
PharmaTher evaluates safety, tolerability and efficacy of low-dose ketamine infusion for treatment of LID in Parkinson’s Disease patients....
Core One Labs appears to be following in footsteps of Mind Cure, but that doesn't mean the entire psychedelics industry...
Our resident Psychedelic Investor James Hallifax looks at the pros and cons of this Canadian-based company developing DMT for therapeutic...
This week in psychedelic business news: A psychedelics company folds; Ketamine Wellness Centers expand; Nova Mentis funds psilocybin studies....